{
  "meta": {
    "title": "2_Pharmacodynamics",
    "url": "https://brainandscalpel.vercel.app/2-pharmacodynamics-f9a5e63d.html",
    "scrapedAt": "2025-11-30T12:34:11.091Z"
  },
  "questions": [
    {
      "text": "Neurotransmitters like noradrenaline, adrenaline, and dopamine act on:",
      "choices": [
        {
          "id": 1,
          "text": "Single-pass transmembrane receptors"
        },
        {
          "id": 2,
          "text": "Nuclear receptors"
        },
        {
          "id": 3,
          "text": "Seven-pass transmembrane receptors"
        },
        {
          "id": 4,
          "text": "Ligand-gated receptors"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Noradrenaline</strong>, <strong>adrenaline,</strong> and <strong>dopamine</strong> act&nbsp;through a&nbsp;bundle of <strong>seven</strong> alpha-helicase <strong>trans-membrane</strong> receptors&nbsp;which are the&nbsp;<strong>G-protein-coupled receptors</strong> (GPCRs).</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a4c6a2d30d5c46dc9b527577f6591a2ax1280x1087.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Neurotransmitters and Type of Receptor</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Neurotransmitter </strong></p>\n</td>\n<td>\n<p><strong>Receptor </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glutamate</p>\n</td>\n<td>\n<p>Ligand-gated ion channel-kainate,&nbsp;NMDA, AMPA</p>\n<p>Metabotropic (mGluR)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GABA</p>\n</td>\n<td>\n<p>Ligand-gated (GABA A and GABA C)</p>\n<p>GPCR (GABA B)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Acetylcholine</p>\n</td>\n<td>\n<p>Muscarinic &ndash; GPCR</p>\n<p>Nicotinic &ndash; Ligand</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Norepinephrine</p>\n</td>\n<td>\n<p>GPCR</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Serotonin</p>\n</td>\n<td>\n<p>GPCR (except 5HT3 which is ligand gated)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Dopamine</p>\n</td>\n<td>\n<p>GPCR</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4492",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is true about G-protein-coupled receptors?",
      "choices": [
        {
          "id": 1,
          "text": "G proteins bind to hormones on the cell surface."
        },
        {
          "id": 2,
          "text": "All the three subunits alpha, beta and gamma should bind to each other for G proteins to act."
        },
        {
          "id": 3,
          "text": "G proteins act as inhibitory and excitatory because of differences in the alpha subunit."
        },
        {
          "id": 4,
          "text": "G protein is bound to GTP in resting state."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>G proteins</strong> act as <strong>inhibitory</strong> and <strong>excitatory</strong> because of <strong>differences</strong> in the <strong>alpha</strong> subunit.&nbsp;</p>\n<ul>\n<li><strong>Excitatory -</strong>&nbsp;Gs and Gq&nbsp;</li>\n<li><strong>Inhibitory</strong> -&nbsp;Gi&nbsp;</li>\n</ul>\n<p>In the <strong>resting-state</strong>:</p>\n<ul>\n<li>G protein is a heterotrimer consisting of alpha, beta, and gamma subunits. It forms a complex with G-protein-coupled receptors at the intracellular domain. The extracellular domain of GPCR has the binding domain for hormones. G protein subunits do not directly bind them.<strong>&nbsp;</strong></li>\n<li>The <strong>alpha</strong> subunit is bound to <strong>GDP.</strong>&nbsp;</li>\n</ul>\n<p><strong>Binding </strong>of<strong> ligand </strong>results in<strong>&nbsp;activation of GPCR,&nbsp;</strong>following which:</p>\n<ul>\n<li>Alpha subunit undergoes a conformational change</li>\n<li>Release of GDP and binding of GTP occurs</li>\n<li>GTP bound alpha subunit dissociates from beta-gamma subunit</li>\n<li>Both alpha subunit and beta-gamma subunit bind to and regulate effectors&nbsp;only when they are separated.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b43b24ca1f7244c8b612a11f90812f45x1279x1346.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4495",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following GPCRs does not act via the K+ channel?",
      "choices": [
        {
          "id": 1,
          "text": "Angiotensin 1 receptor"
        },
        {
          "id": 2,
          "text": "Muscarinic M2 receptor"
        },
        {
          "id": 3,
          "text": "Dopamine D2 receptor"
        },
        {
          "id": 4,
          "text": "Serotonin 5 HT1 receptor"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Angiotensin 1 receptor</strong> acts via <strong>Ca<sup>2+</sup></strong> channels. It does not act through second messengers via the K<sup>+</sup> channel.&nbsp;</p>\n<p>G-protein coupled receptors activate inwardly rectifying potassium channels and increase the permeability of the potassium ions causing hyperpolarisation of the cell. They are called <strong>G protein-coupled inwardly-rectifying potassium channels</strong> (GIRKs). These receptors include:</p>\n<ul>\n<li><strong>M2 </strong>muscarinic</li>\n<li><strong>A1 </strong>adenosine</li>\n<li><strong>&alpha;2 </strong>adrenergic</li>\n<li><strong>D2 </strong>dopamine</li>\n<li><strong>5HT1 </strong>serotonin</li>\n<li>Somatostatin receptors.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0131",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is an example of a GPCR?",
      "choices": [
        {
          "id": 1,
          "text": "Muscarinic"
        },
        {
          "id": 2,
          "text": "Nicotinic"
        },
        {
          "id": 3,
          "text": "GABA-A"
        },
        {
          "id": 4,
          "text": "Insulin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Muscarinic receptors</strong> are <strong>G-protein-coupled receptors</strong> among the given options.</p>\n<p>M1, M2, M3, M4, and M5 are the muscarinic&nbsp;Ach receptors.</p>\n<ul>\n<li><strong>M1</strong> and <strong>M3</strong> act through <strong>Gq</strong> protein and activate&nbsp;<strong>IP3/DAG</strong> causing increased cytosolic calcium.</li>\n<li><strong>M2</strong> and <strong>M4</strong> act through&nbsp;<strong>Gi</strong> protein and inhibit <strong>adenylyl cyclase</strong> causing increased potassium conductance.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2fa1475ef8974317bcddf902a641b91cx1280x1087.JPEG\" alt=\"Explanation Image\"><p><strong>Nicotinic receptors</strong> and <strong>GABA-A</strong> are examples of <strong>ion channel</strong> coupled receptors.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/43df5b42a2db476c9dbb0130408366d0x1280x1500.JPEG\" alt=\"Explanation Image\"><p><strong>Insulin</strong> receptor is a <strong>tyrosine kinase</strong> receptor.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/99c758676519450aad00625cacd2b74cx720x1321.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Neurotransmitters and Type of Receptor</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Neurotransmitter </strong></p>\n</td>\n<td>\n<p><strong>Receptor </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glutamate</p>\n</td>\n<td>\n<p>Ligand-gated ion channel-kainate,&nbsp;NMDA, AMPA</p>\n<p>Metabotropic (mGluR)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GABA</p>\n</td>\n<td>\n<p>Ligand-gated (GABA A and GABA C)</p>\n<p>GPCR (GABA B)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Acetylcholine</p>\n</td>\n<td>\n<p>Muscarinic &ndash; GPCR</p>\n<p>Nicotinic &ndash; Ligand</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Norepinephrine</p>\n</td>\n<td>\n<p>GPCR</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Serotonin</p>\n</td>\n<td>\n<p>GPCR (except 5HT3 which is ligand gated)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Dopamine</p>\n</td>\n<td>\n<p>GPCR</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5340",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is an ion channel receptor?",
      "choices": [
        {
          "id": 1,
          "text": "Nicotinic cholinergic receptor"
        },
        {
          "id": 2,
          "text": "Muscarinic cholinergic receptor"
        },
        {
          "id": 3,
          "text": "Beta adrenergic receptors"
        },
        {
          "id": 4,
          "text": "Opioid receptors"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Nicotinic cholinergic receptors</strong> (both Nm and Nn) are of <strong>ligand-gated</strong> ion channel type.</p>\n<p>The binding of ligand alters the <strong>permeability</strong> of <strong>ion channels</strong> directly and brings about <strong>biological action.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/33cfea1bc6f2417cbc712880cb653c8ex1280x1500.JPEG\" alt=\"Explanation Image\"><p>Muscarinic cholinergic, beta-adrenergic, and opioid receptors are G protein-coupled receptors.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f9c1a274c2964d6f80153a48471ace73x1279x1086.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4502",
      "difficulty": "easy"
    },
    {
      "text": "All of the following agents act by intracellular receptors except ______",
      "choices": [
        {
          "id": 1,
          "text": "Thyroid hormones"
        },
        {
          "id": 2,
          "text": "Vitamin D"
        },
        {
          "id": 3,
          "text": "Insulin"
        },
        {
          "id": 4,
          "text": "Steroid"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Insulin</strong> receptors belong to the class of<strong> trans-membrane</strong> enzyme-linked receptors.</p>\n<p><strong>Transmembrane enzyme-linked receptors </strong>consist of a<strong>&nbsp;</strong>large extracellular ligand-binding domain. It is connected to an intracellular subunit having enzymatic property through a single transmembrane helical peptide chain. The enzyme on the cytosolic side is usually a <strong>protein kinase</strong> (tyrosine) or <strong>membrane-bound GC&nbsp;</strong>(guanylyl cyclase).</p>\n<p>Physiological ligands for transmembrane enzyme-linked receptors are mostly growth factors and chemokines. Other receptors belonging to this class include:</p>\n<ul>\n<li><strong>Receptor tyrosine kinases -&nbsp;</strong>Growth factors (PDGF, EGF, VEGF); insulin</li>\n</ul>\n<ul>\n<li><strong>Membrane-bound GC -&nbsp;</strong>Natriuretic peptides</li>\n</ul>\n<ul>\n<li><strong>Receptor serine-threonine kinases -&nbsp;</strong>TGF-&beta;&nbsp;</li>\n</ul>\n<p>Thyroid hormones, vitamin D, and steroids act via intracellular receptors.&nbsp;</p><hr><h3>Related Pearl: Mechanisms of Action of Hormones</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Types of hormone receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to intracellular receptors</strong></td>\n</tr>\n<tr>\n<td rowspan=\"3\">Cytoplasmic receptors</td>\n<td>Glucocorticoids</td>\n</tr>\n<tr>\n<td>Mineralocorticoids</td>\n</tr>\n<tr>\n<td>Androgens</td>\n</tr>\n<tr>\n<td> </td>\n<td>Vitamin D</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Nuclear receptors</td>\n<td>Thyroid hormones</td>\n</tr>\n<tr>\n<td>Vitamins A</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to cell surface receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\">1. <strong>G-protein coupled receptors</strong> (GPCR)</td>\n</tr>\n<tr>\n<td rowspan=\"9\"><strong>Gs</strong>: stimulation of second messenger cAMP</td>\n<td>ACTH, CRH</td>\n</tr>\n<tr>\n<td>TSH, GHRH</td>\n</tr>\n<tr>\n<td>FSH, LH, hCG</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Catecholamines (β receptors)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td>Glucagon</td>\n</tr>\n<tr>\n<td>Secretin</td>\n</tr>\n<tr>\n<td>Parathyroid hormone</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>Gi: </strong>inhibition of second messenger cAMP</td>\n<td>Catecholamines (ɑ<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Acetylcholine (M2, M4)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td rowspan=\"11\">\n<p><strong>Gq</strong>: second messenger is phospholipase C or cGMP</p>\n</td>\n<td><strong>Phospholipase C (IP3 DAG pathway):</strong></td>\n</tr>\n<tr>\n<td>GnRH, GHRH, TRH</td>\n</tr>\n<tr>\n<td>Catecholamines (ɑ<sub>1</sub> receptors)</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>1</sub> receptor)</td>\n</tr>\n<tr>\n<td>Gastrin</td>\n</tr>\n<tr>\n<td>Cholecystokinin</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td>Acetylcholine (M1, M3, M5)</td>\n</tr>\n<tr>\n<td><strong>cGMP:</strong></td>\n</tr>\n<tr>\n<td>Atrial natriuretic peptide</td>\n</tr>\n<tr>\n<td>Nitric oxide</td>\n</tr>\n<tr>\n<td colspan=\"2\">2. <strong>Tyrosine kinase</strong> receptors</td>\n</tr>\n<tr>\n<td rowspan=\"5\">Through the <strong>JAK-STAT</strong> (non-receptor tyrosine kinase) or <strong>MAP kinase</strong> (receptor tyrosine kinase) pathway </td>\n<td>Growth factors like IGF, VEGF, FGF, PDGF</td>\n</tr>\n<tr>\n<td>Growth hormone</td>\n</tr>\n<tr>\n<td>Erythropoietin</td>\n</tr>\n<tr>\n<td>Insulin</td>\n</tr>\n<tr>\n<td>Prolactin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Notes: <br />1. Even though the cytoplasmic receptors are present in the cytoplasm, once the <strong>hormone-receptor complex</strong> is formed it moves to the <strong>nucleus</strong> for its actions.</p>\n<p>2. <strong>Vitamin D</strong> is a <strong>cytoplasmic receptor.</strong> All intracellular receptors are inherently nuclear receptors as they bind and get activated at the nucleus as mentioned above but they have two sites of primary action- cytoplasm and nucleus. </p>\n<p>3. While receptor tyrosine kinases have intrinsic tyrosine kinase activity, non-receptor tyrosine kinases have an external tyrosine kinase component that interacts with the receptor as and when required. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4503",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following is not a second messenger?",
      "choices": [
        {
          "id": 1,
          "text": "Cyclic AMP"
        },
        {
          "id": 2,
          "text": "Guanylyl cyclase"
        },
        {
          "id": 3,
          "text": "Diacylglycerol"
        },
        {
          "id": 4,
          "text": "Inositol triphosphate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Guanylyl cyclase</strong>&nbsp;is an <strong>enzyme</strong> that converts <strong>GTP</strong> to <strong>cGMP.</strong> It is not a second messenger.</p>\n<p><strong>Second messengers</strong> are:</p>\n<ul>\n<li>Diacylglycerol</li>\n<li>Inositol triphosphate</li>\n<li>Cyclic AMP</li>\n<li>Cyclic GMP</li>\n<li>Calcium</li>\n<li>Nitric oxide</li>\n</ul><hr><h3>Related Pearl: Mechanisms of Action of Hormones</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Types of hormone receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to intracellular receptors</strong></td>\n</tr>\n<tr>\n<td rowspan=\"3\">Cytoplasmic receptors</td>\n<td>Glucocorticoids</td>\n</tr>\n<tr>\n<td>Mineralocorticoids</td>\n</tr>\n<tr>\n<td>Androgens</td>\n</tr>\n<tr>\n<td> </td>\n<td>Vitamin D</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Nuclear receptors</td>\n<td>Thyroid hormones</td>\n</tr>\n<tr>\n<td>Vitamins A</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to cell surface receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\">1. <strong>G-protein coupled receptors</strong> (GPCR)</td>\n</tr>\n<tr>\n<td rowspan=\"9\"><strong>Gs</strong>: stimulation of second messenger cAMP</td>\n<td>ACTH, CRH</td>\n</tr>\n<tr>\n<td>TSH, GHRH</td>\n</tr>\n<tr>\n<td>FSH, LH, hCG</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Catecholamines (β receptors)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td>Glucagon</td>\n</tr>\n<tr>\n<td>Secretin</td>\n</tr>\n<tr>\n<td>Parathyroid hormone</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>Gi: </strong>inhibition of second messenger cAMP</td>\n<td>Catecholamines (ɑ<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Acetylcholine (M2, M4)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td rowspan=\"11\">\n<p><strong>Gq</strong>: second messenger is phospholipase C or cGMP</p>\n</td>\n<td><strong>Phospholipase C (IP3 DAG pathway):</strong></td>\n</tr>\n<tr>\n<td>GnRH, GHRH, TRH</td>\n</tr>\n<tr>\n<td>Catecholamines (ɑ<sub>1</sub> receptors)</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>1</sub> receptor)</td>\n</tr>\n<tr>\n<td>Gastrin</td>\n</tr>\n<tr>\n<td>Cholecystokinin</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td>Acetylcholine (M1, M3, M5)</td>\n</tr>\n<tr>\n<td><strong>cGMP:</strong></td>\n</tr>\n<tr>\n<td>Atrial natriuretic peptide</td>\n</tr>\n<tr>\n<td>Nitric oxide</td>\n</tr>\n<tr>\n<td colspan=\"2\">2. <strong>Tyrosine kinase</strong> receptors</td>\n</tr>\n<tr>\n<td rowspan=\"5\">Through the <strong>JAK-STAT</strong> (non-receptor tyrosine kinase) or <strong>MAP kinase</strong> (receptor tyrosine kinase) pathway </td>\n<td>Growth factors like IGF, VEGF, FGF, PDGF</td>\n</tr>\n<tr>\n<td>Growth hormone</td>\n</tr>\n<tr>\n<td>Erythropoietin</td>\n</tr>\n<tr>\n<td>Insulin</td>\n</tr>\n<tr>\n<td>Prolactin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Notes: <br />1. Even though the cytoplasmic receptors are present in the cytoplasm, once the <strong>hormone-receptor complex</strong> is formed it moves to the <strong>nucleus</strong> for its actions.</p>\n<p>2. <strong>Vitamin D</strong> is a <strong>cytoplasmic receptor.</strong> All intracellular receptors are inherently nuclear receptors as they bind and get activated at the nucleus as mentioned above but they have two sites of primary action- cytoplasm and nucleus. </p>\n<p>3. While receptor tyrosine kinases have intrinsic tyrosine kinase activity, non-receptor tyrosine kinases have an external tyrosine kinase component that interacts with the receptor as and when required. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4508",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following hormones act through the receptor shown in the image below?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin"
        },
        {
          "id": 2,
          "text": "Somatostatin"
        },
        {
          "id": 3,
          "text": "Cholecystokinin"
        },
        {
          "id": 4,
          "text": "Vasopressin (V1 receptor)"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The receptor in the given image uses <strong>tyrosine kinase</strong> signaling.<strong>&nbsp;Insulin&nbsp;</strong>acts through this receptor to exert its functions.</p>\n<p>Other hormones acting via tyrosine kinase signaling:&nbsp;</p>\n<ul>\n<li>Growth hormone</li>\n<li>Growth factors like VEGF, PDGF, FGF, NGF</li>\n<li>Prolactin</li>\n<li>Leptin</li>\n</ul><hr><h3>Related Pearl: Mechanisms of Action of Hormones</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Types of hormone receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to intracellular receptors</strong></td>\n</tr>\n<tr>\n<td rowspan=\"3\">Cytoplasmic receptors</td>\n<td>Glucocorticoids</td>\n</tr>\n<tr>\n<td>Mineralocorticoids</td>\n</tr>\n<tr>\n<td>Androgens</td>\n</tr>\n<tr>\n<td> </td>\n<td>Vitamin D</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Nuclear receptors</td>\n<td>Thyroid hormones</td>\n</tr>\n<tr>\n<td>Vitamins A</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to cell surface receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\">1. <strong>G-protein coupled receptors</strong> (GPCR)</td>\n</tr>\n<tr>\n<td rowspan=\"9\"><strong>Gs</strong>: stimulation of second messenger cAMP</td>\n<td>ACTH, CRH</td>\n</tr>\n<tr>\n<td>TSH, GHRH</td>\n</tr>\n<tr>\n<td>FSH, LH, hCG</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Catecholamines (β receptors)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td>Glucagon</td>\n</tr>\n<tr>\n<td>Secretin</td>\n</tr>\n<tr>\n<td>Parathyroid hormone</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>Gi: </strong>inhibition of second messenger cAMP</td>\n<td>Catecholamines (ɑ<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Acetylcholine (M2, M4)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td rowspan=\"11\">\n<p><strong>Gq</strong>: second messenger is phospholipase C or cGMP</p>\n</td>\n<td><strong>Phospholipase C (IP3 DAG pathway):</strong></td>\n</tr>\n<tr>\n<td>GnRH, GHRH, TRH</td>\n</tr>\n<tr>\n<td>Catecholamines (ɑ<sub>1</sub> receptors)</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>1</sub> receptor)</td>\n</tr>\n<tr>\n<td>Gastrin</td>\n</tr>\n<tr>\n<td>Cholecystokinin</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td>Acetylcholine (M1, M3, M5)</td>\n</tr>\n<tr>\n<td><strong>cGMP:</strong></td>\n</tr>\n<tr>\n<td>Atrial natriuretic peptide</td>\n</tr>\n<tr>\n<td>Nitric oxide</td>\n</tr>\n<tr>\n<td colspan=\"2\">2. <strong>Tyrosine kinase</strong> receptors</td>\n</tr>\n<tr>\n<td rowspan=\"5\">Through the <strong>JAK-STAT</strong> (non-receptor tyrosine kinase) or <strong>MAP kinase</strong> (receptor tyrosine kinase) pathway </td>\n<td>Growth factors like IGF, VEGF, FGF, PDGF</td>\n</tr>\n<tr>\n<td>Growth hormone</td>\n</tr>\n<tr>\n<td>Erythropoietin</td>\n</tr>\n<tr>\n<td>Insulin</td>\n</tr>\n<tr>\n<td>Prolactin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Notes: <br />1. Even though the cytoplasmic receptors are present in the cytoplasm, once the <strong>hormone-receptor complex</strong> is formed it moves to the <strong>nucleus</strong> for its actions.</p>\n<p>2. <strong>Vitamin D</strong> is a <strong>cytoplasmic receptor.</strong> All intracellular receptors are inherently nuclear receptors as they bind and get activated at the nucleus as mentioned above but they have two sites of primary action- cytoplasm and nucleus. </p>\n<p>3. While receptor tyrosine kinases have intrinsic tyrosine kinase activity, non-receptor tyrosine kinases have an external tyrosine kinase component that interacts with the receptor as and when required. </p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/137bbde364aa4bcfbec1d567af3f5776.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0609",
      "difficulty": "easy"
    },
    {
      "text": "A patient with congestive heart failure is being treated with an intravenous infusion of nesiritide. Which of the following receptors does this drug act through?",
      "choices": [
        {
          "id": 1,
          "text": "G-protein coupled receptors"
        },
        {
          "id": 2,
          "text": "Tyrosine kinase receptors"
        },
        {
          "id": 3,
          "text": "JAK-STAT receptors"
        },
        {
          "id": 4,
          "text": "Ligand-gated guanylyl cyclase receptor"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Nesiritide</strong> is recombinant&nbsp;<strong>B-type natriuretic peptide.&nbsp;</strong>Natriuretic peptide receptors are transmembrane <strong>ligand-gated</strong> <strong>guanylyl cyclase</strong> receptors.</p>\n<p>Natriuretic peptides:&nbsp;</p>\n<ul>\n<li><strong>Atrial</strong> <strong>natriuretic peptide</strong> (ANP): released from atrial storage granules in response to an increase in intravascular volume. It <strong>decreases blood pressure</strong>.&nbsp;&nbsp;</li>\n<li><strong>Brain natriuretic peptide</strong> (BNP): released from ventricular tissue in response to volume overload. Along with a decrease in blood pressure, it is known to <strong>reduce cardiac hypertrophy</strong> and<strong> fibrosis</strong>.&nbsp;&nbsp;</li>\n<li><strong>C- type natriuretic peptide</strong> (CNP): synthesized in the brain and endothelial tissues and functions to stimulate <strong>long bone growth.</strong>&nbsp;</li>\n</ul>\n<p>ANP and BNP act on the <strong>NPR-A</strong> receptor.</p>\n<p>CNP acts on the <strong>NPR-B</strong> receptor.&nbsp;</p><hr><h3>Related Pearl: Mechanisms of Action of Hormones</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Types of hormone receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to intracellular receptors</strong></td>\n</tr>\n<tr>\n<td rowspan=\"3\">Cytoplasmic receptors</td>\n<td>Glucocorticoids</td>\n</tr>\n<tr>\n<td>Mineralocorticoids</td>\n</tr>\n<tr>\n<td>Androgens</td>\n</tr>\n<tr>\n<td> </td>\n<td>Vitamin D</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Nuclear receptors</td>\n<td>Thyroid hormones</td>\n</tr>\n<tr>\n<td>Vitamins A</td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Hormones that bind to cell surface receptors</strong></td>\n</tr>\n<tr>\n<td colspan=\"2\">1. <strong>G-protein coupled receptors</strong> (GPCR)</td>\n</tr>\n<tr>\n<td rowspan=\"9\"><strong>Gs</strong>: stimulation of second messenger cAMP</td>\n<td>ACTH, CRH</td>\n</tr>\n<tr>\n<td>TSH, GHRH</td>\n</tr>\n<tr>\n<td>FSH, LH, hCG</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Catecholamines (β receptors)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td>Glucagon</td>\n</tr>\n<tr>\n<td>Secretin</td>\n</tr>\n<tr>\n<td>Parathyroid hormone</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>Gi: </strong>inhibition of second messenger cAMP</td>\n<td>Catecholamines (ɑ<sub>2</sub> receptors)</td>\n</tr>\n<tr>\n<td>Acetylcholine (M2, M4)</td>\n</tr>\n<tr>\n<td>Somatostatin</td>\n</tr>\n<tr>\n<td rowspan=\"11\">\n<p><strong>Gq</strong>: second messenger is phospholipase C or cGMP</p>\n</td>\n<td><strong>Phospholipase C (IP3 DAG pathway):</strong></td>\n</tr>\n<tr>\n<td>GnRH, GHRH, TRH</td>\n</tr>\n<tr>\n<td>Catecholamines (ɑ<sub>1</sub> receptors)</td>\n</tr>\n<tr>\n<td>Vasopressin (V<sub>1</sub> receptor)</td>\n</tr>\n<tr>\n<td>Gastrin</td>\n</tr>\n<tr>\n<td>Cholecystokinin</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td>Acetylcholine (M1, M3, M5)</td>\n</tr>\n<tr>\n<td><strong>cGMP:</strong></td>\n</tr>\n<tr>\n<td>Atrial natriuretic peptide</td>\n</tr>\n<tr>\n<td>Nitric oxide</td>\n</tr>\n<tr>\n<td colspan=\"2\">2. <strong>Tyrosine kinase</strong> receptors</td>\n</tr>\n<tr>\n<td rowspan=\"5\">Through the <strong>JAK-STAT</strong> (non-receptor tyrosine kinase) or <strong>MAP kinase</strong> (receptor tyrosine kinase) pathway </td>\n<td>Growth factors like IGF, VEGF, FGF, PDGF</td>\n</tr>\n<tr>\n<td>Growth hormone</td>\n</tr>\n<tr>\n<td>Erythropoietin</td>\n</tr>\n<tr>\n<td>Insulin</td>\n</tr>\n<tr>\n<td>Prolactin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br />Notes: <br />1. Even though the cytoplasmic receptors are present in the cytoplasm, once the <strong>hormone-receptor complex</strong> is formed it moves to the <strong>nucleus</strong> for its actions.</p>\n<p>2. <strong>Vitamin D</strong> is a <strong>cytoplasmic receptor.</strong> All intracellular receptors are inherently nuclear receptors as they bind and get activated at the nucleus as mentioned above but they have two sites of primary action- cytoplasm and nucleus. </p>\n<p>3. While receptor tyrosine kinases have intrinsic tyrosine kinase activity, non-receptor tyrosine kinases have an external tyrosine kinase component that interacts with the receptor as and when required. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4539",
      "difficulty": "medium"
    },
    {
      "text": "JAK/STAT is a signal transducer for which of the following receptors?",
      "choices": [
        {
          "id": 1,
          "text": "G protein coupled receptors"
        },
        {
          "id": 2,
          "text": "Ion channels"
        },
        {
          "id": 3,
          "text": "Transmembrane receptors"
        },
        {
          "id": 4,
          "text": "Nuclear receptors"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>JAK/STAT</strong> is a signal transducer&nbsp;for <strong>transmembrane receptors</strong> lacking intrinsic enzymatic activity.</p>\n<p><strong>Interleukin </strong>and other <strong>cytokines</strong> act through such receptors.</p>\n<p>On binding of the ligand to such receptors:</p>\n<ul>\n<li>Receptor dimerization occurs</li>\n<li>Increase in affinity for cytosolic JAK (Janus kinase)</li>\n<li>Activation of JAK results in phosphorylation of tyrosine residues of the receptor</li>\n<li>Binding of signal transducer and activator of transcription (STAT) and subsequent phosphorylation of STAT</li>\n<li>STAT dimerizes and translocates to the nucleus to regulate gene expression, resulting in a biological response</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/80e08aee5f19404abcb79703932759f4x1280x2227.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4509",
      "difficulty": "medium"
    },
    {
      "text": "Adrenaline is used to treat histamine-induced bronchoconstriction in a patient with brittle asthma. What is this type of antagonism called?",
      "choices": [
        {
          "id": 1,
          "text": "Physiological antagonism"
        },
        {
          "id": 2,
          "text": "Chemical antagonism"
        },
        {
          "id": 3,
          "text": "Competitive antagonism"
        },
        {
          "id": 4,
          "text": "Uncompetitive antagonism"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Adrenaline</strong> and <strong>histamine</strong> are <strong>physiological</strong> antagonists.&nbsp;</p>\n<p>Adrenaline and histamine act on bronchial muscles. <strong>Histamine</strong> acts on <strong>H1</strong> receptors and produces <strong>bronchoconstriction. Adrenaline</strong> acts on&nbsp;<strong>&beta;2&nbsp;</strong>receptors and produces <strong>bronchodilation.&nbsp;</strong>Two drugs acting on different receptors and resulting in opposite responses means having <strong>pharmacological effects</strong> in the <strong>opposite</strong> direction. This is called&nbsp;<strong>physiological</strong> antagonism or <strong>functional</strong> antagonism.</p>\n<div class=\"page\" title=\"Page 77\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Option B:<strong> Chemical</strong> antagonism refers to a reaction between two chemicals to neutralize their effects, such as is seen with <strong>chelation</strong> therapy.</p>\n<div class=\"page\" title=\"Page 54\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Option C:&nbsp;<strong>Competitive</strong> antagonism is a type of <strong>receptor</strong> antagonism that occurs when the agonist and antagonist compete for the <strong>same</strong> binding <strong>site</strong> on the receptor.</p>\n<p>Option D: In<strong> uncompetitive inhibition,&nbsp;</strong>inhibitors form a complex with an intermediate complex of the substrate and transporter. This inhibits subsequent translocation.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4521",
      "difficulty": "medium"
    },
    {
      "text": "Diamox is given to a patient with glaucoma. It is a non-competitive inhibitor of the carbonic anhydrase enzyme. Which of the following would be the effect of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Decrease in Vmax"
        },
        {
          "id": 2,
          "text": "Decrease in Km"
        },
        {
          "id": 3,
          "text": "Decrease in both Km and Vmax"
        },
        {
          "id": 4,
          "text": "No change in Vmax"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Non-competitive inhibitors</strong> cause <strong>a decrease in Vmax.</strong></p>\n<p>In non-competitive inhibition:</p>\n<ul>\n<li>The inhibitor<strong> binds</strong> to the<strong> adjacent site</strong> and not the catalytic site of the enzyme</li>\n<li>The catalytic property of the enzyme is reduced and hence<strong>&nbsp;Vmax </strong>is<strong> decreased</strong></li>\n<li>The affinity of the enzyme is not altered and hence&nbsp;<strong>Km</strong> is<strong> unaltered</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/28ef8e94d26446bbbe7383b757789868x1280x1423.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7026",
      "difficulty": "medium"
    },
    {
      "text": "Letrozole, a competitive inhibitor of the enzyme aromatase is prescribed to a patient with breast cancer. Which of the following is true about this type of antagonism?",
      "choices": [
        {
          "id": 1,
          "text": "Antagonism cannot be completely reversed by increased dose of the agonist"
        },
        {
          "id": 2,
          "text": "An agonist cannot displace an antagonist from the receptor"
        },
        {
          "id": 3,
          "text": "Agonists and antagonists bind to the same receptor"
        },
        {
          "id": 4,
          "text": "Dose response curve shifts to the left in the presence of an antagonist"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In <strong>competitive antagonism</strong>, the drug and the antagonist <strong>compete</strong>&nbsp;to bind to the<strong> same site </strong>of the receptor.</p>\n<p>Agonists if present in high concentration, can displace the antagonists from the active site and overcome the competitive antagonism completely.</p>\n<p>The <strong>dose-response</strong> curve in the case of <strong>competitive antagonism</strong> shifts to the <strong>right.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4524",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true regarding the dose-response curve shown in the image below?",
      "choices": [
        {
          "id": 1,
          "text": "C is competitive antagonist"
        },
        {
          "id": 2,
          "text": "C is more potent than A"
        },
        {
          "id": 3,
          "text": "B is more potent than A"
        },
        {
          "id": 4,
          "text": "B is competitive antagonist"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the above image, <strong>drug B</strong> is a <strong>competitive</strong> antagonist.</p>\n<p>In <strong>competitive antagonism,</strong> the DRC is <strong>shifted to the right</strong> whereas in <strong>non-competitive antagonism </strong>the DRC is <strong>flattened</strong>.</p>\n<p>Thus in the above image Drug B is the Competitive antagonist while <strong>drug C</strong> is the <strong>non-competitive</strong> antagonist.</p>\n<p><strong>Potency:</strong></p>\n<ul>\n<li>It is defined as the&nbsp;<strong>amount</strong> of<strong> drug&nbsp;</strong>needed&nbsp;to<strong> produce </strong>a given<strong> response.</strong></li>\n<li>A&nbsp;<strong>highly potent drug</strong>&nbsp;evokes a given&nbsp;<strong>response</strong> at<strong> low concentrations</strong>&nbsp;and vice-versa.</li>\n<li>The&nbsp;<strong>more</strong> the<strong> curve</strong> is on the<strong> left&nbsp;</strong>in a dose-response curve (DRC)<strong>, </strong>the<strong> greater</strong> is its<strong> potency.</strong></li>\n<li>Thus, in the above image, the potency is drug A &gt; drug C &gt; drug B.</li>\n</ul>\n<p><strong>Efficacy:</strong></p>\n<ul>\n<li>It is defined as the<strong>&nbsp;maximum effect produced</strong>&nbsp;by the drug.</li>\n<li>It expresses the effect produced by the receptors when bound by a certain drug.</li>\n<li>In the log dose-response curve, the&nbsp;<strong>perpendicular height</strong>&nbsp;represents the drug efficacy.</li>\n<li>Thus, in the above image, the efficacy is drug A = drug B &gt; drug C.</li>\n</ul>",
      "question_images": [
        "https://daily-rounds-staging.s3.amazonaws.com/uploads/1b116b337c9d4636888a2aa8223e3636.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8346",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a true statement regarding inverse agonists?",
      "choices": [
        {
          "id": 1,
          "text": "Binds to the receptor and causes maximum action"
        },
        {
          "id": 2,
          "text": "Binds to the receptor and causes opposite action to that of agonist"
        },
        {
          "id": 3,
          "text": "Binds to the receptor and causes no action"
        },
        {
          "id": 4,
          "text": "Binds to the receptor and causes submaximal action"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Inverse agonists</strong> bind to the receptor and cause an action<strong>&nbsp;opposite </strong>to that of an<strong> agonist.</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type of drugs</strong></p>\n</td>\n<td>\n<p><strong>Intrinsic activity</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Agonists</p>\n</td>\n<td>\n<p>1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Partial agonists</p>\n</td>\n<td>\n<p>0 to 1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Competitive antagonists</p>\n</td>\n<td>\n<p>0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inverse agonists</p>\n</td>\n<td>\n<p>0 to -1</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The ability of the drug <strong>to bind</strong> with a receptor is called <strong>affinity.</strong></p>\n<p>The capacity of a drug to induce a functional change in the receptor is called&nbsp;intrinsic activity or efficacy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4516",
      "difficulty": "easy"
    },
    {
      "text": "A patient with symptoms of psychosis is prescribed aripiprazole. Which of the following best describes this drug?",
      "choices": [
        {
          "id": 1,
          "text": "No intrinsic activity and high affinity for D2 receptor"
        },
        {
          "id": 2,
          "text": "High intrinsic activity and no affinity for D2 receptor"
        },
        {
          "id": 3,
          "text": "Low intrinsic activity and high affinity for D2 receptor"
        },
        {
          "id": 4,
          "text": "High intrinsic activity and low affinity for D2 receptor"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Aripiprazole is a D2 receptor <strong>partial agonist</strong>. Partial agonists have submaximal or <strong>low intrinsic activity</strong> and <strong>high affinity.</strong></p>\n<p>Partial agonists can behave as an antagonist in the presence of an agonist. Partial agonists <strong>block</strong> the <strong>binding</strong> of the <strong>agonist</strong> to the receptor thereby <strong>inhibit</strong>ing a <strong>complete response.</strong></p>\n<p>Aripiprazole has lower activity than dopamine at D2 receptors.&nbsp;By occupying and blocking the action of dopamine on D2 receptors, it acts similar to an antagonist. It is used in conditions like schizophrenia where dopamine antagonist activity is required.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4535",
      "difficulty": "medium"
    },
    {
      "text": "What type of antagonism is shown by drugs A and B in the following dose-response curve?",
      "choices": [
        {
          "id": 1,
          "text": "Competitive antagonism"
        },
        {
          "id": 2,
          "text": "Noncompetitive antagonism"
        },
        {
          "id": 3,
          "text": "Uncompetitive antagonism"
        },
        {
          "id": 4,
          "text": "Cannot be determined"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The<strong> parallel rightward shift </strong>of the agonist dose-response curve (DRC) is seen with<strong> competitive antagonism.</strong></p>\n<p>Increasing the dose of the agonist can result in the same maximal response.</p>\n<p>In <strong>non-competitive antagonism</strong>, there will be <strong>flattening</strong> of the agonist DRC.</p>\n<div class=\"page\" title=\"Page 89\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p> </p>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6211b2beb2fc444faebd7f4ab50b4f84x1280x1167.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/70f71508943a49488767fd1ac5304e71.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4523",
      "difficulty": "easy"
    },
    {
      "text": "The graph below shows the relationship between the log(dose) and the response of three drugs, A, B, and C. Which of these drugs has the highest potency?",
      "choices": [
        {
          "id": 1,
          "text": "A"
        },
        {
          "id": 2,
          "text": "B"
        },
        {
          "id": 3,
          "text": "Both A and B"
        },
        {
          "id": 4,
          "text": "C"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Drug A</strong> has the highest potency.</p>\n<p><strong>Potency:</strong></p>\n<ul>\n<li>It is defined as the <strong>amount </strong>of drug needed to <strong>produce</strong> a<strong> given response.&nbsp;</strong>A&nbsp;<strong>highly potent drug</strong>&nbsp;evokes a given&nbsp;<strong>response </strong>at<strong> low concentrations</strong>&nbsp;and vice-versa.</li>\n<li>The more the curve is on the<strong> left </strong>in a dose-response curve (DRC)<strong>, </strong>the <strong>greater </strong>is its<strong> potency.&nbsp;</strong></li>\n<li>Thus, in the above image, the potency is Drug A &gt;Drug B&gt; Drug C.</li>\n</ul>\n<p><strong>Efficacy:</strong></p>\n<ul>\n<li>It is defined as the<strong> maximum effect</strong> produced by the drug. It reflects the capacity of the drug to activate a receptor and produce the response.</li>\n<li>In the log dose-response curve, the <strong>perpendicular height</strong> represents the drug efficacy.</li>\n<li>Thus, in the above image, the efficacy is Drug A = Drug B &gt; Drug C.</li>\n<li>Drugs having a similar pharmacological effect can have different efficacies e.g furosemide and metolazone are both diuretics but furosemide has greater efficacy than metolazone.&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b45dbf4ee48b4afaac794cf75bab570a.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0607",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true about the given dose-response curve?",
      "choices": [
        {
          "id": 1,
          "text": "Drug B is the most potent."
        },
        {
          "id": 2,
          "text": "Drug B is the most efficacious."
        },
        {
          "id": 3,
          "text": "Drug C is more efficacious than drug D."
        },
        {
          "id": 4,
          "text": "Drug A is more potent than drug B."
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>more</strong> the<strong> curve</strong> is on the<strong> left </strong>in a dose-response curve (DRC)<strong>,</strong> the<strong> greater</strong> is its<strong> potency. </strong>Hence<strong>,&nbsp;</strong>Drug B is the most potent.</p>\n<p><strong>Potency:</strong></p>\n<ul>\n<li>It is defined as the <strong>amount of drug </strong>needed<strong> to produce a given response.</strong></li>\n<li>A&nbsp;<strong>highly potent drug</strong>&nbsp;evokes a given&nbsp;<strong>response at low concentrations</strong>&nbsp;and vice-versa.</li>\n<li>In the above image, the potency is Drug B&gt; Drug A &gt; Drug C &gt; Drug D.</li>\n</ul>\n<p><strong>Efficacy:</strong></p>\n<ul>\n<li>It is defined as the<strong>&nbsp;maximum effect</strong>&nbsp;produced by the drug. It reflects the <strong>capacity</strong> of the drug <strong>to activate</strong> a receptor and <strong>produce</strong> the <strong>response.</strong></li>\n<li>In the log dose-response curve, the&nbsp;<strong>perpendicular height</strong>&nbsp;represents the drug efficacy.</li>\n<li>Thus, in the above image, the efficacy is Drug A = Drug C =Drug D &gt; Drug B.</li>\n<li>Drugs having a similar pharmacological effect can have different efficacies e.g furosemide and metolazone are both diuretics but furosemide has greater efficacy than metolazone.&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/a55588364afa413da3c7cb8df6bfc3f5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3672",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements regarding the potency and efficacy of a drug is not true?",
      "choices": [
        {
          "id": 1,
          "text": "In a clinical setup, efficacy is more important than potency"
        },
        {
          "id": 2,
          "text": "In the log dose response curve, the height of the curve corresponds with efficacy"
        },
        {
          "id": 3,
          "text": "ED50 of the drug corresponds to the efficacy"
        },
        {
          "id": 4,
          "text": "Drugs that produce a similar pharmacological effect can have different levels of efficacy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>ED50 </strong>is a measure of the <strong>drug potency,</strong> not efficacy.</p>\n<p>Potency refers to the amount of the drug required to produce a certain response. The x coordinates (dose axis) on the log dose-response curve (DRC) of a drug represent the potency of the drug. A right shift in the DRC indicates a lower potency and vice versa.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/12fda29ce9db479e99be322d78892dc3x1280x1196.JPEG\" alt=\"Explanation Image\"><p><strong>Potency</strong></p>\n<ul>\n<li>It is defined as the <strong>amount of drug </strong>needed<strong> to produce a given response.</strong></li>\n<li>A&nbsp;<strong>highly potent drug</strong>&nbsp;evokes a given&nbsp;<strong>response at low concentrations</strong>&nbsp;and vice-versa.</li>\n<li>The efficacy of a drug is a more decisive factor in the choice of a drug in the clinical setting</li>\n<li>The <strong>more the curve shifts towards the left&nbsp;</strong>in a dose-response curve (DRC)<strong>, the greater is its potency.</strong></li>\n<li>Thus, in the above image, Drug A is more potent. The potency is&nbsp; Drug A &gt; Drug B &gt; Drug C &gt; Drug D.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/202d58649a0544a9ba61ef918f0a6f03x1280x1167.JPEG\" alt=\"Explanation Image\"><p><strong>Efficacy</strong></p>\n<ul>\n<li>It is defined as the<strong> maximum effect produced</strong> by the drug.</li>\n<li>It expresses the effect produced by the receptors when bound by a certain drug.</li>\n<li>It is mainly a factor in choosing the dose of a drug.</li>\n<li>In the log dose-response curve, the <strong>perpendicular height</strong> represents the drug efficacy.</li>\n<li>Thus, in the above image, efficacy is Drug A &gt;B &gt; C &gt; D.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4515",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following shows a U-shaped dose-response curve?",
      "choices": [
        {
          "id": 1,
          "text": "Vitamins"
        },
        {
          "id": 2,
          "text": "Anti-cancer drugs"
        },
        {
          "id": 3,
          "text": "Steroids"
        },
        {
          "id": 4,
          "text": "Chelators"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Vitamins</strong> and <strong>essential metals</strong> show a <strong>U-shaped dose-response curve</strong>.</p>\n<div class=\"page\" title=\"Page 74\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>At a <strong>low dose,</strong> adverse effects are observed because there is a <strong>deficiency</strong> of these nutrients to maintain homeostasis. As <strong>dose increases, homeostasis</strong> is achieved, and the bottom of the U-shaped dose-response curve is reached. As the <strong>dose increases</strong> to surpass the amount required to maintain homeostasis, <strong>toxicity</strong> can ensue.</p>\n<p>Thus, <strong>adverse effects</strong> are seen at both <strong>low</strong> and<strong> high doses. </strong></p>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cbb79628483a49e5bce96265d68a0673x1280x1154.JPEG\" alt=\"Explanation Image\"><p class=\"p1\"><strong>Hockey stick-shaped dose-response</strong> curve for <strong>toxicants</strong> that are also metabolic by-products. </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e0db32ffbadd42dd9c69b75a9398ff60x1280x1420.JPEG\" alt=\"Explanation Image\"><p class=\"p1\"><strong>Inverted U-shaped</strong> dose-response curve for <strong>ligands</strong> that <strong>downregulate their receptors.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/23699bc3b29d46ed9c13c1f6a2abef2cx1280x1282.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4914",
      "difficulty": "hard"
    },
    {
      "text": "What does the area between the dotted lines in this graph indicate?",
      "choices": [
        {
          "id": 1,
          "text": "Median effective dose"
        },
        {
          "id": 2,
          "text": "Median lethal dose"
        },
        {
          "id": 3,
          "text": "Therapeutic index"
        },
        {
          "id": 4,
          "text": "Therapeutic window"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The area between the dotted lines in the graph shows the<strong>&nbsp;therapeutic window</strong>. It is the <strong>range</strong> of <strong>steady-state concentrations</strong> of a drug that provides <strong>therapeutic efficacy</strong> with <strong>minimal toxicity.</strong></p>\n<p>The<strong> therapeutic index</strong> (TI) describes a relationship between the doses of a drug that causes lethal or toxic effects with the dose that causes therapeutic effects. It is also called the therapeutic ratio.</p>\n<p>Mathematically, you can calculate TI by following way:</p>\n<p>Therapeutic Index =<strong> LD<sub>50</sub>/ED<sub>50</sub></strong>&nbsp;(or)&nbsp;Therapeutic Index =<strong> TD<sub>50</sub>/ED<sub>50</sub></strong></p>\n<p>Where,</p>\n<ul>\n<li><strong>LD<sub>50</sub></strong>&nbsp;(Median Lethal dose) is the minimum amount of drug that causes adverse effects in 50% of the population.&nbsp;<strong>LD<sub>50</sub></strong>&nbsp;could also be replaced with Toxic dose (<strong>TD<sub>50</sub></strong>).</li>\n<li><strong>ED<sub>50</sub></strong>&nbsp;(Median Effective dose) is the quantity of a drug that can produce desired therapeutic effects in 50% of the population.</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/13fba814599e4468b06f6230f1b67101.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6481",
      "difficulty": "medium"
    },
    {
      "text": "Therapeutic index is used for assessing which of the following factors?",
      "choices": [
        {
          "id": 1,
          "text": "Safety"
        },
        {
          "id": 2,
          "text": "Efficacy"
        },
        {
          "id": 3,
          "text": "Potency"
        },
        {
          "id": 4,
          "text": "Toxicity"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Therapeutic index</strong> is used to assess the <strong>safety </strong>of the drug administered.</p>\n<p>Therapeutic index = TD50/ED50&nbsp;</p>\n<ul>\n<li><strong>TD50</strong> (Median toxic dose) = Dose required to produce a toxic effect in 50% of animals tested.</li>\n<li><strong>ED50</strong> (Median effect dose) = Dose required to produce a therapeutic effect in 50% of the individuals.</li>\n</ul>\n<p>Option B: <strong>Efficacy</strong>&nbsp;is defined as the<strong> maximum effect produced</strong> by the drug. It&nbsp;expresses the effect produced by the receptors when bound by a certain drug.</p>\n<p>Option C:<strong> Potency </strong>refers to the <strong>concentration</strong> (EC50) or dose (ED50) <strong>required</strong> to <strong>produce 50%</strong> of <strong>maximum effect</strong> where EC50 is the concentration of agonist resulting in a half-maximal response.</p>\n<p>Option D: <strong>Median toxic dose</strong> is the dose required to produce a <strong>toxic effect</strong> in <strong>50%</strong> of <strong>animals tested.</strong> Lethal dose is the dose required to kill 50% of animals tested.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3486",
      "difficulty": "medium"
    },
    {
      "text": "Therapeutic index is calculated with which of the following equations?",
      "choices": [
        {
          "id": 1,
          "text": "ED50/LD50"
        },
        {
          "id": 2,
          "text": "LD50/ED50"
        },
        {
          "id": 3,
          "text": "ED50-LD50"
        },
        {
          "id": 4,
          "text": "ED50 X LD50"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Therapeutic index </strong>is calculated with the following equation =<strong>&nbsp;LD50/ED50.</strong></p>\n<p>Therapeutic index is used to assess the <strong>safety </strong>of the drug administered.</p>\n<p><strong>LD50</strong> (median lethal dose) refers to the dose of the drug at which <strong>50%</strong> of the experimental<strong> animals die.</strong>&nbsp;Larger the LD50, the safer the drug. In humans, <strong>TD50</strong> is considered.&nbsp;TD50 refers to the dose of the drug that causes a <strong>toxic response</strong> in <strong>50%</strong> of the <strong>population.</strong></p>\n<p><strong>ED50</strong> (median effective dose) refers to the dose of the drug at which <strong>50%</strong> of the experimental <strong>animals</strong> show the <strong>specific</strong> or <strong>desired effect</strong></p>\n<p>Clinically, the therapeutic range <strong>bound</strong> by the dose that produces the minimal <strong>necessary</strong> therapeutic effect and the dose that produces the maximal <strong>acceptable</strong> adverse effect is more relevant.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1355a1cb0a574d2e9c6bd3789144d0e4x1280x1420.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4527",
      "difficulty": "easy"
    },
    {
      "text": "Calculate the therapeutic index of a drug whose dose-response curves are plotted as shown below:",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "2"
        },
        {
          "id": 3,
          "text": "4"
        },
        {
          "id": 4,
          "text": "8"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>therapeutic index</strong> is <strong>4</strong>.</p>\n<p>In the above graph,</p>\n<p>Median lethal dose (LD50) = 400</p>\n<p>Median effective dose (ED50) = 100</p>\n<p><strong>Therapeutic index (TI)</strong> =<strong> LD50/ED50.</strong></p>\n<p>Hence,</p>\n<p>Therapeutic index (TI ) = 400/100 = 4</p>\n<p>Clinically, the therapeutic range bound by the dose that produces the minimal therapeutic effect and the dose that produces the maximal acceptable adverse effect is more relevant.</p>\n<p> </p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/622c455438be4ab480ed5ee698509c1f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2315",
      "difficulty": "easy"
    },
    {
      "text": "Therapeutic drug monitoring is required in all except ______.",
      "choices": [
        {
          "id": 1,
          "text": "Phenytoin"
        },
        {
          "id": 2,
          "text": "Metformin"
        },
        {
          "id": 3,
          "text": "Tacrolimus"
        },
        {
          "id": 4,
          "text": "Cylcosporine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Metformin</strong> does not require therapeutic monitoring because it<strong> does not have </strong>a<strong>&nbsp;narrow therapeutic index</strong> and the effect on blood sugar levels can be easily measured.</p>\n<p>Phenytoin, tacrolimus, and cyclosporine have the narrow therapeutic index and therapeutic monitoring is necessary to avoid adverse effects.</p><hr><h3>Related Pearl: Drugs which need Therapeutic Drug Monitoring (TDM)</h3><p>Drugs with a narrow therapeutic index require therapeutic drug monitoring (TDM).</p>\n<p>The mnemonic \"<strong>DATLAAT MC</strong>\" can be used.</p>\n<ul>\n<li><strong>D</strong>: Digoxin</li>\n<li><strong>A</strong>: Anti-arrhythmic</li>\n<li><strong>T</strong>: Theophylline</li>\n<li><strong>L</strong>: Lithium</li>\n<li><strong>A</strong>: Aminoglycosides</li>\n<li><strong>A</strong>: Anti-epileptics</li>\n<li><strong>T</strong>: Tricyclic antidepressants</li>\n<li><strong>M</strong>: Methotrexate</li>\n<li><strong>C</strong>: Calcineurin inhibitors</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4529",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements about pharmacogenetics is correct?",
      "choices": [
        {
          "id": 1,
          "text": "It refers to the effect of drugs on genetic expression"
        },
        {
          "id": 2,
          "text": "It refers to the genetic basis of variability in drug response"
        },
        {
          "id": 3,
          "text": "It is not synonymous with pharmacogenomics"
        },
        {
          "id": 4,
          "text": "Drug metabolism is not a highly heritable trait"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Pharmacogenetics</strong> is the study of the <strong>genetic basis</strong> for <strong>variability</strong> in <strong>drug action.</strong></p>\n<p>Genetic differences cause&nbsp;variability in the<strong> dose-response curve</strong> (DRC) due to alteration in drug action and disposition in the body.</p>\n<p>The term is used interchangeably with <strong>pharmacogenomics.</strong></p>\n<p><span>Drug metabolism is <strong>highly heritable</strong>, as assessed using drug exposure studies in monozygotic versus fraternal twins and from other related subjects.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4538",
      "difficulty": "medium"
    },
    {
      "text": "A 23-year-old male is diagnosed with G6PD deficiency. Which of the following drugs is not contraindicated in his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Cotrimoxazole"
        },
        {
          "id": 2,
          "text": "Proguanil"
        },
        {
          "id": 3,
          "text": "Nalidixic acid"
        },
        {
          "id": 4,
          "text": "Ceftriaxone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Ceftriaxone</strong> is not contraindicated in G6PD deficient individuals as it does <strong>not</strong> possess <strong>oxidizing property</strong>, hence there is <strong>no hemolysis.</strong></p>\n<p><strong>Drugs</strong> having the <strong>potential</strong> to cause <strong>hemolysis</strong> in <strong>G6PD</strong> deficient individuals:</p>\n<ul>\n<li>Anti-malarials - Primaquine, chloroquine, quinine, pyrimethamine, <strong>proguanil</strong></li>\n<li>Sulfonamides -&nbsp;<strong>Cotrimoxazole</strong></li>\n<li>Fluoroquinolones -&nbsp;<strong>Nalidixic acid</strong></li>\n<li>Nitro furan antibacterial - Furazolidone, nitrofurantoin</li>\n<li>Anti-hypertensives - Methyldopa, hydralazine</li>\n<li>Anti-convulsants - Phenytoin</li>\n<li>Anti-arrythmics - Procainamide</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA4540",
      "difficulty": "medium"
    }
  ]
}